Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. (Q33865523)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

review article

1 reference

title

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author

Martin J van den Bent

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Terri S Armstrong

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Adam D Waldman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

J S Wefel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

D Schiff

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

M J B Taphoorn

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

K Jaeckle

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

L Junck

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

A Choucair

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

T Gorlia

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

M Chamberlain

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

B G Baumert

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

M A Vogelbaum

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

D R Macdonald

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

D A Reardon

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

P Y Wen

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

S M Chang

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

A H Jacobs

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

5 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

27 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

583-593

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.

27 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group stud

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Prognostic factors for survival in adult patients with cerebral low-grade glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Preoperative prognostic classification system for hemispheric low-grade gliomas in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Gain of chromosome 7, as detected by in situ hybridization, strongly correlates with shorter survival in astrocytoma grade 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

MGMT methylation: a marker of response to temozolomide in low-grade gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Low-grade oligodendroglioma responds to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Prognostic significance of imaging contrast enhancement for WHO grade II gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Continuous growth of mean tumor diameter in a subset of grade II gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

FLAIR imaging in the follow-up of low-grade gliomas: time to dispense with the dual-echo?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Magnetic resonance image registration and subtraction in the assessment of minor changes in low grade glioma volume.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Dynamic history of low-grade gliomas before and after temozolomide treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

11C-methionine PET for differential diagnosis of low-grade gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Enhanced accuracy in differential diagnosis of radiation necrosis by positron emission tomography-magnetic resonance imaging coregistration: technical case report.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

The prognostic significance of patient-reported outcomes in cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Seizure characteristics and control following resection in 332 patients with low-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Net clinical benefit: functional endpoints in brain tumor clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Preferential brain locations of low-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Symptoms experience: a concept analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Symptom indexes to assess outcomes of treatment for early prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Depression in patients with high-grade glioma: results of the Glioma Outcomes Project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Epilepsy in low‐grade gliomas: The impact on cognitive function and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Surgical treatment of patients with low-grade astrocytomas and medically intractable seizures.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Epilepsy and brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Measuring the efficacy of antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

Active control trials: endpoints beyond conventional efficacy and tolerability measures

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970057-2

7 January 2021

10.1016/S1470-2045(11)70057-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474379%20AND%20SRC:MED&resulttype=core&format=json

release_4qnfkbvveffcncmjl2uidbj67y

27 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4qnfkbvveffcncmjl2uidbj67y

24 November 2022

mapped directly with Wikidata item

1 reference